Brief: Harris & Harris Group says FDA clears Mersana's IND application for conjugate XMT-1522
24/10/2016 16:56
Oct 24 (Reuters) - Harris And Harris Group Inc TINY.O :
* Harris & Harris Group Portfolio Company, Mersana
Therapeutics, announces FDA clearance of ind application for
lead antibody-drug conjugate XMT-1522
* Mersana will get $20 million milestone payment based on
FDA clearance of IND application for antibody-drug conjugate
XMT-1522
Source text for Eikon: ID:nGNXNKJPFa
Further company coverage: TINY.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on 180 Degree Capital
See all newsBrief: Marlton Partners Comments On 180 Degree Capital Corp. And Mount Logan Capital Business Combination
Brief: 180 Degree Capital Corp. And Mount Logan Capital Inc. Announce Revised Terms Of Business Combination In Response To Constructive Conversations With Shareholders
Brief: 180 Degree Capital Corp. And Mount Logan Capital Inc. Provide Update On Proposed Business Combination
Brief: Marlton Partners Owns 5.2% Of 180 Degree Capital
Brief: 180 Degree Capital Says New Entity To Be Listed On Nasdaq As MLCI